CPT code 87538 denotes a laboratory molecular diagnostic assay using an amplified probe technique to definitively identify HIV–2 infection. This code captures specialized confirmatory testing beyond routine HIV screening, and it is clinically important for accurate diagnosis, appropriate patient management, and public health surveillance of HIV–2. Accurate coding enables labs and payers to classify and process claims for these higher-complexity diagnostic services.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. These payers commonly cover laboratory diagnostic services, though specific coverage policies, prior authorization requirements, and payment rates vary by plan and clinical criteria.

Readers will learn the clinical context and service setting for 87538, how the code is used for confirmatory HIV–2 testing, and what national payers typically consider when adjudicating claims for molecular infectious disease assays. The publication provides benchmarks and policy-oriented discussion relevant to billing, coding accuracy, and payer policy updates for specialized HIV diagnostic testing. Data not available in the input where specific payer policy details, associated taxonomies, ICD-10 mappings, and related codes would normally be summarized.